Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.: What Does It Mean for Investors and the World?
On January 22, 2025, The Schall Law Firm announced that it had filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (Regeneron or the Company) in the United States District Court for the Southern District of New York. The lawsuit alleges that Regeneron violated the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder during the period from November 2, 2023, to October 30, 2024 (the “Class Period”).
Allegations Against Regeneron
The complaint asserts that Regeneron made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the lawsuit alleges that Regeneron downplayed the risks associated with its drug, Eylea, and failed to disclose that its sales growth was due to price increases rather than new prescriptions. These allegations came to light when the Company announced disappointing third-quarter earnings in October 2024.
Impact on Investors
The lawsuit could have significant implications for Regeneron investors who purchased the Company’s securities during the Class Period. If the allegations are proven true, these investors may be entitled to damages. The Schall Law Firm encourages investors to contact it before March 10, 2025, to discuss their legal rights.
Impact on the World
The lawsuit against Regeneron is part of a larger trend of increased scrutiny on the pharmaceutical industry. In recent years, there have been numerous cases of drug companies facing lawsuits over pricing and marketing practices. This trend is likely to continue as regulators and investors demand greater transparency and accountability.
Conclusion
The class action lawsuit against Regeneron Pharmaceuticals, Inc. is a reminder of the importance of transparency and honesty in the pharmaceutical industry. Investors who purchased Regeneron’s securities during the Class Period may be entitled to damages if the allegations are proven true. The lawsuit is also part of a larger trend of increased scrutiny on the pharmaceutical industry, which is likely to continue in the coming years.
- Regeneron Pharmaceuticals, Inc. faces a class action lawsuit alleging violations of securities laws.
- The lawsuit pertains to the period from November 2, 2023, to October 30, 2024.
- The allegations include downplaying risks and failing to disclose material information regarding Eylea.
- The lawsuit could have significant implications for Regeneron investors.
- The lawsuit is part of a larger trend of increased scrutiny on the pharmaceutical industry.
